Literature DB >> 16296812

Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism.

Andreas Pfützner1, Thomas Forst.   

Abstract

Technosphere/Insulin (TI) is a formulation of regular human insulin designed for efficient transport across the respiratory epithelium into the circulation. The drug carrier mechanism achieves a fast systemic insulin uptake (maximum time approximately 15-20 min), a fast onset of action (maximum activity approximately 25-30 min) and a short duration of action (approximately 2 h). Bioavailability, relative to subcutaneous injection, was established to be between 30 and 50% with a linear dose-response relationship and low variability. In all published short-term studies, TI was well tolerated. Provided a reliable long-term safety profile, TI may become a suitable alternative to subcutaneous injection for prandial insulin delivery. TI offers the possibility of new treatment regimens, especially in patients with Type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296812     DOI: 10.1517/17425247.2.6.1097

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  12 in total

Review 1.  Devices for dry powder drug delivery to the lung.

Authors:  Kai Berkenfeld; Alf Lamprecht; Jason T McConville
Journal:  AAPS PharmSciTech       Date:  2015-05-12       Impact factor: 3.246

2.  Challenges and Future Prospects for the Delivery of Biologics: Oral Mucosal, Pulmonary, and Transdermal Routes.

Authors:  Javier O Morales; Kristin R Fathe; Ashlee Brunaugh; Silvia Ferrati; Song Li; Miguel Montenegro-Nicolini; Zeynab Mousavikhamene; Jason T McConville; Mark R Prausnitz; Hugh D C Smyth
Journal:  AAPS J       Date:  2017-02-13       Impact factor: 4.009

3.  Inspiratory efforts achieved in use of the Technosphere insulin inhalation system.

Authors:  Chad C Smutney; Emil M Friedman; John M Polidoro; Nikhil Amin
Journal:  J Diabetes Sci Technol       Date:  2009-09-01

4.  Technosphere insulin: defining the role of Technosphere particles at the cellular level.

Authors:  Robert Angelo; Kathleen Rousseau; Marshall Grant; Andrea Leone-Bay; Peter Richardson
Journal:  J Diabetes Sci Technol       Date:  2009-05-01

Review 5.  Controlled release of biologics for the treatment of type 2 diabetes.

Authors:  Caslin A Gilroy; Kelli M Luginbuhl; Ashutosh Chilkoti
Journal:  J Control Release       Date:  2015-12-02       Impact factor: 9.776

6.  Psychometric properties of an instrument for assessing the experience of patients treated with inhaled insulin: the inhaled insulin treatment questionnaire (IITQ).

Authors:  Richard R Rubin; Mark Peyrot
Journal:  Health Qual Life Outcomes       Date:  2010-03-24       Impact factor: 3.186

7.  Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes.

Authors:  Klaus Rave; Tim Heise; Lutz Heinemann; Anders H Boss
Journal:  J Diabetes Sci Technol       Date:  2008-03

Review 8.  Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin.

Authors:  Anders H Boss; Richard Petrucci; Daniel Lorber
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

9.  Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.

Authors:  Julio Rosenstock; Richard Bergenstal; Ralph A Defronzo; Irl B Hirsch; David Klonoff; Anders H Boss; David Kramer; Richard Petrucci; Wen Yu; Brian Levy
Journal:  Diabetes Care       Date:  2008-08-04       Impact factor: 17.152

10.  Formulation, physicochemical characterization and in vitro evaluation of human insulin-loaded microspheres as potential oral carrier.

Authors:  Gauravkumar R Agrawal; Pravin Wakte; Santosh Shelke
Journal:  Prog Biomater       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.